AdaptHealth Corp vs 10X Genomics Inc — how do they compare? AdaptHealth Corp trades at $5.8 (market cap $753.09M), while 10X Genomics Inc trades at $57.68 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 10.1× AdaptHealth Corp's market cap, and 10X Genomics Inc is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | TXG | |
|---|---|---|
Market Cap | $753.09M | $7.61B |
Sector | Health | Health |
52-Week High | $13.38 | $58.57 |
52-Week Low | $5.22 | $11.34 |
Enterprise Value | $2.77B | $7.14B |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →